Loading...
XTAI
3054
Market cap146mUSD
Oct 08, Last price  
58.10TWD
1D
-1.36%
1Q
-8.36%
Jan 2017
100.87%
IPO
-74.06%
Name

LIWANLI Innovation Co Ltd

Chart & performance

D1W1MN
XTAI:3054 chart
P/E
29.63
P/S
37.33
EPS
1.96
Div yield, %
—
Shrs. gr., 5y
-0.66%
Rev. gr., 5y
-14.63%
Revenues
126m
+26.61%
1,243,110,0001,019,155,0002,317,240,0002,736,562,0002,443,691,0002,235,930,000834,909,000323,097,000348,213,000185,512,000129,782,000276,879,00047,813,00033,988,00038,887,00099,156,000125,540,000
Net income
158m
P
86,816,000117,287,00035,782,000-58,152,000289,775,00015,304,000-103,453,00062,796,00081,910,000891,0002,782,000-13,613,00045,563,000-120,907,0005,103,000-32,074,000158,146,000
CFO
-72m
L
89,430,00078,412,000-157,772,000-104,023,000-89,820,000473,038,00034,044,000112,684,00096,034,000-123,090,000-109,160,000-36,627,000-61,133,00078,479,000-50,343,00014,202,000-71,778,000
Dividend
Jun 26, 20260.8 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

LIWANLI Innovation Co., Ltd. operates within the biomedical science sector, concentrating on the development and distribution of nutrition and healthcare solutions. The company's diverse product portfolio, which notably features the Vigoway line and various powdered formulations, is designed to serve a wide range of consumers, including men, women, seniors, and children. Its extensive offerings encompass products such as probiotic enzymes, active nutrients, resveratrol red grape extract, and a variety of soft gels (including those with algae DHA, shea butter with type II collagen, and algae astaxanthin Q10). Other specialized items include cordyceps militaris powder, tooth guard tablets, bovine and goat's milk bites, bilberry tablets, and DHA and vitamin D3 drops, among others. The firm was formerly known as Carry Technology International Co., Ltd. before officially adopting its current name, LIWANLI Innovation Co., Ltd., in 2015. Established in 1980, the company's headquarters are located in New Taipei City, Taiwan.

Key people

Jason Chen
Chairman of the Board, General Manager · since 2008
Mizhang Chen
Deputy General Manager, Director · since 2005
Darong Zhang
Deputy General Manager · since 2011
Teng-Yin Chang
Head of Finance & Accounting · since 2026
Yu-Yen Hsieh
Corporate Governance Officer · since 2026
Zhiqing Gao
Director
Shizhe Luo
Director · since 2020
Wenyuan Zhang
Director · since 2020
Wen-Ru Hsu
Independent Director · since 2023
Ching-Ju Li
Independent Director · since 2025
Yu-Ming Yu
Independent Director · since 2023
IPO date
Jul 22, 2002
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT